2002062347

01 OCT 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/82895 A3

(51) International Patent Classification[7]: A61K 9/20

(21) International Application Number: PCT/US01/13379

(22) International Filing Date: 26 April 2001 (26.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/559,542 28 April 2000 (28.04.2000) US

(71) Applicant *(for all designated States except US)*: **ADAMS LABORATORIES, INC.** [US/US]; 14801 Sovereign Road, Fort Worth, TX 76155-2645 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BLUME, Ralph, W.** [US/US]; 6709 Welch Avenue, Fort Worth, TX 76133 (US). **DAVIS, Robert, D.** [US/US]; 1600 Ridge Haven Drive, Apt. 208, Arlington, TX 76011 (US). **KEYSER, Donald, J.** [US/US]; 1216 Wyndham Hill Lane, Southlake, TX 76092 (US).


(74) Agents: **TATE, Rodger, L.** et al.; Intellectual Property Department, Brobeck, Phleger & Harrison LLP, 1333 H Street, N.W., Suite 800, Washington, DC 20005 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: GUAIFENESIN SUSTAINED RELEASE FORMULATION AND TABLETS



(57) Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-one (6:1), more preferably a range of about three-to-two (3:2) to about four-to-one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has two portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above. This two portion, or bi-layer, tablet has a maximum serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.

WO 01/82895 A3

162162

ACTION

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
23 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.